Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus
VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial
fibrillation) in a real-life setting